Pages that link to "Q36298955"

The following pages link to Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance (Q36298955):

Displaying 19 items.

• Solving the puzzle of autoimmunity: critical questions (Q28084677) (← links)
• Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis (Q28535303) (← links)
• Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis (Q34355672) (← links)
• Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. (Q34513928) (← links)
• Multiple sclerosis: modulation of toll-like receptor (TLR) expression by interferon-β includes upregulation of TLR7 in plasmacytoid dendritic cells (Q34947419) (← links)
• A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis (Q35568496) (← links)
• Identifying Multi-Dimensional Co-Clusters in Tensors Based on Hyperplane Detection in Singular Vector Spaces (Q36123914) (← links)
• The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases (Q36338717) (← links)
• Role of toll-like receptors in multiple sclerosis (Q37021687) (← links)
• MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients (Q37139127) (← links)
• Multiple sclerosis treatment and infectious issues: update 2013. (Q38153471) (← links)
• Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis. (Q38687394) (← links)
• Disease-modifying therapies and infectious risks in multiple sclerosis (Q38760860) (← links)
• Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. (Q39130808) (← links)
• Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy (Q41102110) (← links)
• Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. (Q51025796) (← links)
• Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. (Q53178623) (← links)
• Elastic net-based prediction of IFN-β treatment response of patients with multiple sclerosis using time series microarray gene expression profiles (Q61796751) (← links)
• Feature selection based on differentially correlated gene pairs reveals the mechanism of IFN-β therapy for multiple sclerosis (Q90642111) (← links)